Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
NCT05743881Phase 1Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Feb 2023
- Primary completion
- Aug 2029
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of RNA-100-AR02 and mRNA-1365 in respiratory syncytial virus infection (RSV) and human metapneumovirus infection (HMPV) (10 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions, Number of Participants with Unsolicited Adverse Events and 3 more. Started Feb 2023; status: active, not recruiting.
02
Drugs
RNA-100-AR02mRNA-1365
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NCT05743881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743881.